BCR and leukemia: The patient-derived xenograft (PDX) mice succumbed to their leukemia at a median of 76 and 78 days (Figure 1F; p = 0.0207 and p = 0.0295, respectively, compared with the BCR::ABL1 control with a median survival of 278 days).